Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

ASCLETIS Aktie

 >ASCLETIS Aktienkurs 
1.03 EUR    +4.0%    (Tradegate)
Ask: 1.09 EUR / 3197 Stück
Bid: 1.03 EUR / 3406 Stück
Tagesumsatz: 1300 Stück
Realtime Kurs von 8 bis 22 Uhr!
ASCLETIS Aktie über LYNX handeln
>ASCLETIS Performance
1 Woche: -1,0%
1 Monat: +44,6%
3 Monate: -6,4%
6 Monate: +209,3%
1 Jahr: +853,7%
laufendes Jahr: +176,9%
>ASCLETIS Aktie
Name:  ASCLETIS PHARMA DL-,0001
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  KYG0520K1094 / A2JRKN
Symbol/ Ticker:  2VJ (Frankfurt)
Kürzel:  FRA:2VJ, ETR:2VJ, 2VJ:GR
Index:  -
Webseite:  http://www.ascletis.com.c..
Marktkapitalisierung:  819.34 Mio. EUR
Umsatz:  1.12 Mio. EUR
EBITDA:  -342.63 Mio. EUR
Gewinn je Aktie:  -0.035 EUR
Schulden:  6.7 Mio. EUR
Liquide Mittel:  1711.19 Mio. EUR
Umsatz-/ Gewinnwachstum:  -87.3% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  5490 / 3.44 / -
Gewinnm./ Eigenkapitalr.:  - / -13.97%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  ASCLETIS
Letzte Datenerhebung:  22.06.25
>ASCLETIS Eigentümer
Aktien: 962.44 Mio. St.
f.h. Aktien: 132.12 Mio. St.
Insider Eigner: 75.38%
Instit. Eigner: 0.4%
Leerverk. Aktien: -
>ASCLETIS Peer Group

 
18.06.25 - 02:03
 Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis (PR Newswire)
 
- The Phase I trial evaluates the safety, tolerability and preliminary efficacy of ASC50 for the treatment of psoriasis. - Preclinical data, including higher oral exposure, longer half-life and strong efficacy, support ASC50 as a potential best-in-class once-daily oral agent for the......
09.06.25 - 02:18
 Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA) (PR Newswire)
 
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will......
04.06.25 - 01:18
 Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints (PR Newswire)
 
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability......
22.05.25 - 12:42
 Ascletis Pharma Reports IND Clearance Of ASC50 (AFX)
 
BEIJING (dpa-AFX) - Ascletis Pharma said the FDA has cleared the investigational new drug application for a Phase I trial for ASC50 for the treatment of mild-to-moderate plaque psoriasis. ASC50 is......
22.05.25 - 12:02
 Ascletis Announces U.S. FDA Clearance of IND Application for Its Oral Small Molecule IL-17 Inhibitor, ASC50, for the Treatment of Psoriasis (PR Newswire)
 
-- ASC50 is an in-house discovered and developed oral small molecule interleukin-17 (IL-17) inhibitor for the treatment of multiple autoimmune and inflammatory diseases, including psoriasis. -- Following oral dosing in non-human primates, ASC50 demonstrated higher drug exposure, longer......
20.05.25 - 12:01
 Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity (PR Newswire)
 
- The combination study is designed to evaluate the safety and preliminary efficacy of a single-dose of ultra-long-acting subcutaneously administered ASC47 in combination with four doses of semaglutide (0.5 mg, once-weekly) in participants with obesity. - As an adipose-targeted,......
06.05.25 - 10:57
 Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity (PR Newswire)
 
HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd European Congress On......
23.04.25 - 04:12
 Ascletis Pharma Reports Positive Phase Ib Results For ASC30 In Treating Obesity (AFX)
 
BEIJING (dpa-AFX) - Ascletis Pharma Inc. (ASCLF.PK) announced positive topline results from its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study of ASC30 o......
23.04.25 - 01:33
 Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA (PR Newswire)
 
- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 mg doses. - ASC30 oral once-daily tablet also demonstrated a 4.5% placebo-adjusted mean......
31.03.25 - 13:03
 Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist (PR Newswire)
 
-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supporting once monthly or less frequent administration. -As previously disclosed, oral tablet formulation of small molecule ASC30 demonstrated......
20.03.25 - 12:00
 Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025 (PR Newswire)
 
HONG KONG, March 20, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces it will host an Obesity Portfolio Webinar on April 2, 2025, from 9:00 a.m. – 10:30 a.m. ET. The event will include a detailed discussion on Ascletis' obesity portfolio including exciting data......
12.03.25 - 05:01
 Ascletis Announces Positive ASC47 Phase Ib Pharmacokinetic & Weight Loss Data From Australia Studies (AFX)
 
BEIJING (dpa-AFX) - Ascletis Pharma Inc. (ASCLF.PK) announced promising pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies conducted in Australia. P......
12.03.25 - 00:33
 Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide (PR Newswire)
 
ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively, in Phase Ib single subcutaneous injection studies in healthy subjects with elevated low-density lipoprotein......
19.02.25 - 14:48
 Ascletis Pharma Reports Positive Interim Phase 1b Data For ASC30 To Treat Obesity (AFX)
 
BEIJING (dpa-AFX) - Ascletis Pharma Inc. (ASCLF.PK) Wednesday reported positive interim results from the Phase 1b study of ASC30 for the treatment of obesity.The Phase Ib multiple ascending dose (......
21.01.25 - 12:01
 Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update (PR Newswire)
 
ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosing. ASC30 oral tablet was generally safe and well......
17.09.24 - 13:24
 Ascletis Pharma Announces Two Ongoing Phase 1 Studies Of ASC30 To Treat Obesity (AFX)
 
BEIJING (dpa-AFX) - Ascletis Pharma Inc. (ASCLF.PK) Monday announced initiation of two Phase 1 studies evaluating ASC30 as both once-monthly subcutaneous injection and once-daily oral tablet for t......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ein dummer Bodybuilder redet Maskulatur. - Dr. Fritz P. Rinnhofer
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!